RT Journal Article
SR Electronic
T1 Machine Learning Reveals the Contribution of Rare Genetic Variants and Enhances Risk Prediction for Coronary Artery Disease in the Japanese Population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.13.24311909
DO 10.1101/2024.08.13.24311909
A1 Ieki, Hirotaka
A1 Ito, Kaoru
A1 Zhang, Sai
A1 Koyama, Satoshi
A1 Kjellberg, Martin
A1 Yoshida, Hiroki
A1 Kurosawa, Ryo
A1 Matsunaga, Hiroshi
A1 Miyazawa, Kazuo
A1 Enzan, Nobuyuki
A1 Kim, Changhoon
A1 Seo, Jeong-Sun
A1 Higasa, Koichiro
A1 Ozaki, Kouichi
A1 Onouchi, Yoshihiro
A1 The Biobank Japan Project
A1 Matsuda, Koichi
A1 Kamatani, Yoichiro
A1 Terao, Chikashi
A1 Matsuda, Fumihiko
A1 Snyder, Michael
A1 Komuro, Issei
YR 2024
UL http://medrxiv.org/content/early/2024/08/13/2024.08.13.24311909.abstract
AB Genome-wide association studies (GWASs) have advanced our understanding of coronary artery disease (CAD) genetics and enabled the development of polygenic risk scores (PRSs) for estimating genetic risk based on common variant burden. However, GWASs have limitations in analyzing rare variants due to insufficient statistical power, thereby constraining PRS performance. Here, we conducted whole genome sequencing of 1,752 Japanese CAD patients and 3,019 controls, applying a machine learning-based rare variant analytic framework. This approach identified 59 CAD-related genes, including known causal genes like LDLR and those not previously captured by GWASs. A rare variant-based risk score (RVS) derived from the framework significantly predicted CAD cases and cardiovascular mortality in an independent cohort. Notably, combining the RVS with traditional PRS improved CAD prediction compared to PRS alone (area under the curve, 0.66 vs 0.61; p=0.007). Our analyses reinforce the value of incorporating rare variant information, highlighting the potential for more comprehensive genetic assessment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Japan Agency for Medical Research and Development (AMED) under grant numbers JP24bm1423005, JP24km0405209, JP24tm0524004, JP24tm0624002, JP24km0405209, JP24ek0210164, JP17km0305002 and JP17km0305001 and JP24tm0624002. K.I. and K.O. are supported by the Research Funding for Longevity Sciences from the NCGG (24 15). The Nagahama study was supported by a JSPS Grant in Aid for Scientific Research (C), KAKENHI grant numbers JP17K07255 and JP17KT0125, and the Practical Research Project for Rare/Intractable Diseases from AMED under grant numbers JP16ek0109070, JP18kk0205008, JP18kk0205001, JP19ek0109283, and JP19ek0109348.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Biobank Japan and Nagahama cohort IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.